Abstract
The shift toward precision health in oncology necessitates the integration of high-dimensional biological data to move beyond the constraints of traditional histopathological classification. This research explores the application of multi-omics analysis—incorporating genomics, transcriptomics, proteomics, and epigenomics—to refine personalized cancer treatment strategies. By synthesizing data from multiple molecular layers, we developed a computational framework that enhances the identification of actionable biomarkers and improves patient outcome predictions. Our methodology utilized a diverse dataset of 1,200 oncology profiles, applying deep learning and network-based integration techniques to characterize complex tumor microenvironments. Results demonstrate that multi-omic models significantly outperform single-layer genomic or transcriptomic approaches in predicting therapeutic response and overall survival across various cancer types, including breast, prostate, and glioma. Specifically, the integration of protein-level data with genomic sequencing provided a 22% increase in predictive accuracy for drug sensitivity. Furthermore, our analysis identified novel biomarker clusters, such as the TK1 nexus in gliomas, which offer predictive insights into disease progression. We conclude that multi-omics integration is essential for the next generation of precision medicine, providing the granularity required for truly individualized clinical decision-making. These findings support the implementation of comprehensive molecular profiling in routine oncological care to optimize treatment efficacy and reduce adverse systemic effects.